Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis

Blood

Volumn 101, Issue 10, 2003, Pages 3835-3839

  Borgmann, Anja ^a   Von Stackelberg, Arend ^b   Hartmann, Reinhard ^b   Ebell, Wolfram ^b   Klingebiel, Thomas ^b   Peters, Christina ^b   Henze, Günter ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL COUNT; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOLOGY; RECURRENT DISEASE; T LYMPHOCYTE; TIME;

ADOLESCENT; ADULT; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; RECURRENCE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0038603106     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V101.10.3835     Document Type: Article

References (25)

1. Henze G, Fengler R, Hartmann R. Chemotherapy for relapsed childhood acute lymphoblastic leukemia: results of the BFM Study Group. Haematol Blood Transfus. 1994;36:374-379.
2. Borgmann A, Hartmann R, Schmid H, et al. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. Bone Marrow Transplant. 1995;15:515-521.
3. Bührer C, Hartmann R, Fengler R, et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1993;21:470-476.
4. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group. Blood. 1991;78:1166-1172.
5. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM Study Group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2000;14:2205-2222.
6. Harms DO, Janka-Schaub GE. Co-Operative Study Group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia. 2000;14:2234-2239.
7. Blasczyk R, Hahn U, Wehling J, et al. Complete subtyping of the HLA-A locus by sequence-specific amplification followed by direct sequencing or single-strand confirmation polymorphism analysis. Tissue Antigens. 1995;46:86-95.
8. Dopfer R, Henze G, Bender-Götze C, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood. 1991;78:2780-2784.
9. Bührer C, Hartmann R, Fengler R, et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. J Clin Oncol. 1996;14:2812-2817.
10. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1996;9:191-192.
11. Oakhill A, Pamphilon DH, Potter MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. British J Haematol. 1996;94:574-578.
12. Balduzzi A, Gooley T, Anasetti C, et al. Unrelated donor marrow transplantation in children. Blood. 1995;86:3247-3256.
13. Russell CA, Heilmann C, Madsen HO, et al. The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;27:949-958.
14. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998;22:1177-1185.
15. Davies SM, Wagner JE, Weisdorf DJ, et al. Unrelated donor bone marrow transplantation for hematological malignancies-current status. Leuk Lymphoma. 1996;23:221-226.
16. Kroger N, Zabelina T, Kruger W, et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with antithymocyte globulin. Br J Haematol. 2001;113:1060-1071.
17. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
18. Dopfer R, Niethammer D. Report on the International Workshop of the Kind Philipp Foundation on late effects after bone marrow transplantation in childhood malignancies. Pediatr Hematol Oncol. 1993;10:63-84.
19. Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study. Br J Haematol. 2000;108:531-543.
20. Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997;90:2962-2968.
21. Saarinen-Pihkala UM, Gustafsson G, Ringdén O, et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol. 2001;19:3406-3414.
22. Bunin N, Carston M, Wall D, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood. 2002;99:3151-3157.
23. Beyermann B, Adams HP, Henze G. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 1997;15:2231-2237.
24. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92:4072-4079.
25. Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358:1239-1241.